Licensing status

Publication and contact information



VEGF receptor 1 (FLT1; VEGFR-1)

In vitro and mouse studies suggest increasing monocyte production of soluble FLT1 could enhance the effects of therapeutic antibodies against cancer. In cultured peripheral blood monocytes, stimulation and activation with IgG or therapeutic antibodies increased soluble FLT1 levels compared with no stimulation. In human umbilical vein endothelial cells, supernatant from stimulated monocytes containing soluble FLT1 inhibited angiogenesis compared with supernatant from unstimulated cells. In a mouse model of cancer, a neutralizing antibody targeting soluble FLT1 weakened the anticancer effect of a therapeutic antibody. Next steps could include evaluating the combination of soluble FLT1 and a therapeutic mAb in animal cancer models.

SciBX 6(34); doi:10.1038/scibx.2013.924
Published online Sept. 5, 2013

Patent and licensing status unavailable

Justiniano, S.E. et al. J. Biol. Chem.; published online July 31, 2013;
Contact: Susheela Tridandapani,
The Ohio State University, Columbus, Ohio